NECAP2

Summary

NECAP2 (NECAP endocytosis associated 2, HGNC:25528) is a protein-coding gene on chromosome 1p36.13, encoding Adaptin ear-binding coat-associated protein 2 (Q9NVZ3). Involved in endocytosis.

This gene likely encodes a member of the adaptin-ear-binding coat-associated protein family. Studies of a similar protein in rat suggest a role in clathrin-mediated endocytosis. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 55707 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 54 total
• MANE Select transcript: NM_018090

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25528
Approved symbol	NECAP2
Name	NECAP endocytosis associated 2
Location	1p36.13
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10420
Ensembl gene	ENSG00000157191
Ensembl biotype	protein_coding
OMIM	611624
Entrez	55707

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 10 protein_coding, 4 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000337132, ENST00000443980, ENST00000457722, ENST00000459640, ENST00000486390, ENST00000492095, ENST00000496239, ENST00000504551, ENST00000504858, ENST00000508680, ENST00000509727, ENST00000513161, ENST00000893001, ENST00000893002, ENST00000916911, ENST00000916912, ENST00000966887, ENST00000966888

RefSeq mRNA: 3 — MANE Select: NM_018090 NM_001145277, NM_001145278, NM_018090

CCDS: CCDS173, CCDS44066, CCDS44067

Canonical transcript exons

ENST00000337132 — 8 exons

Exon	Start	End
ENSE00001697570	16440724	16440853
ENSE00001816052	16458842	16460078
ENSE00003460799	16449093	16449201
ENSE00003467332	16443632	16443732
ENSE00003469983	16448060	16448141
ENSE00003510922	16447870	16447974
ENSE00003551458	16455818	16455893
ENSE00003603219	16451838	16452015

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 97.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 49.3892 / max 302.6389, expressed in 1826 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
969	47.9434	1826
968	1.4458	808

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	97.50	gold quality
granulocyte	CL:0000094	97.27	gold quality
leukocyte	CL:0000738	96.41	gold quality
monocyte	CL:0000576	96.40	gold quality
mononuclear cell	CL:0000842	96.34	gold quality
spleen	UBERON:0002106	96.09	gold quality
lymph node	UBERON:0000029	96.08	gold quality
secondary oocyte	CL:0000655	94.94	gold quality
vermiform appendix	UBERON:0001154	94.67	gold quality
stromal cell of endometrium	CL:0002255	94.53	gold quality
right lung	UBERON:0002167	94.24	gold quality
blood	UBERON:0000178	94.06	gold quality
upper lobe of left lung	UBERON:0008952	94.06	gold quality
skin of leg	UBERON:0001511	93.81	gold quality
lower esophagus mucosa	UBERON:0035834	93.77	gold quality
right ovary	UBERON:0002118	93.60	gold quality
upper lobe of lung	UBERON:0008948	93.59	gold quality
caecum	UBERON:0001153	93.39	gold quality
skin of abdomen	UBERON:0001416	93.39	gold quality
right adrenal gland cortex	UBERON:0035827	93.28	gold quality
left ovary	UBERON:0002119	93.08	gold quality
omental fat pad	UBERON:0010414	93.04	gold quality
right adrenal gland	UBERON:0001233	93.02	gold quality
peritoneum	UBERON:0002358	93.02	gold quality
gall bladder	UBERON:0002110	92.85	gold quality
left adrenal gland	UBERON:0001234	92.80	gold quality
left adrenal gland cortex	UBERON:0035825	92.79	gold quality
adrenal tissue	UBERON:0018303	92.78	gold quality
right testis	UBERON:0004534	92.69	gold quality
esophagus mucosa	UBERON:0002469	92.63	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.89
E-MTAB-5061	no	3.52

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

53 targeting NECAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-7109-5P	99.18	66.13	1057

Literature-anchored findings (GeneRIF, showing 2)

• Describes identification and characterization of rat NECAP1 and NECAP2 and their roles in endocytosis. (PMID:14555962)
• NECAP2 does not regulate the clathrin-mediated endocytosis of these cargos, the degradation of EGFR or the recycling of transferrin along the slow, Rab11-dependent recycling pathway. We show that protein knockdown of NECAP2 leads to enlarged early endosomes and causes the loss of the clathrin adapter AP-1 from the organelle. (PMID:27206861)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	necap2	ENSDARG00000046002
mus_musculus	Necap2	ENSMUSG00000028923
rattus_norvegicus	Necap2	ENSRNOG00000008427
drosophila_melanogaster	CG9132	FBGN0030791
caenorhabditis_elegans		WBGENE00022453

Paralogs (1): NECAP1 (ENSG00000089818)

Protein

Protein identifiers

Adaptin ear-binding coat-associated protein 2 — Q9NVZ3 (reviewed: Q9NVZ3)

Alternative names: NECAP endocytosis-associated protein 2

All UniProt accessions (5): Q9NVZ3, D6RAN6, D6RB24, F6SKB8, H0Y970

UniProt curated annotations — full annotation on UniProt →

Function. Involved in endocytosis.

Subunit / interactions. Interacts with AP1G1 and AP2A1 components of the adapter protein complexes AP-1 and AP-2. Interacts with the GAE domain proteins GGA1, GGA2 and GGA3.

Subcellular location. Cytoplasmic vesicle. Clathrin-coated vesicle membrane. Cell membrane.

Domain organisation. The WXXF motifs mediate binding of accessory proteins to the ear-domain of AP-1, GGAs and AP-2 through hydrophobic interactions. Selective binding to the GAE domains of AP-1 or to the alpha-ear domain of AP-2 is tuned by the acidic context surrounding the motif and the properties of the second residue of the motif itself.

Similarity. Belongs to the NECAP family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9NVZ3-1	1	yes
Q9NVZ3-2	2
Q9NVZ3-3	3
Q9NVZ3-4	4

RefSeq proteins (3): NP_001138749, NP_001138750, NP_060560* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR012466	NECAP_PHear	Domain

Pfam: PF07933

UniProt features (13 total): splice variant 4, region of interest 2, short sequence motif 2, chain 1, sequence variant 1, sequence conflict 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NVZ3-F1	70.65	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 181

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828	Clathrin-mediated endocytosis
R-HSA-199991	Membrane Trafficking
R-HSA-5653656	Vesicle-mediated transport

MSigDB gene sets: 168 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, MODULE_255, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, MODULE_317, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS, GOCC_COATED_VESICLE, GOCC_VESICLE_COAT, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ELK1_01, GOBP_IMPORT_INTO_CELL, CHANDRAN_METASTASIS_UP, GOBP_ENDOCYTOSIS, ISRE_01

GO Biological Process (3): endocytosis (GO:0006897), protein transport (GO:0015031), vesicle-mediated transport (GO:0016192)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): plasma membrane (GO:0005886), clathrin-coated pit (GO:0005905), clathrin vesicle coat (GO:0030125), membrane (GO:0016020), clathrin-coated vesicle membrane (GO:0030665), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Clathrin-mediated endocytosis	1
Membrane Trafficking	1
Vesicle-mediated transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	2
membrane	2
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
intracellular protein localization	1
establishment of protein localization	1
cellular process	1
binding	1
cell periphery	1
endomembrane system	1
clathrin coat	1
vesicle coat	1
clathrin-coated vesicle membrane	1
cellular anatomical structure	1
clathrin-coated vesicle	1
coated vesicle membrane	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

696 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NECAP2	AP2A1	O95782	818
NECAP2	FCHO1	O14526	607
NECAP2	A0A0J9YXS1	A0A0J9YXS1	505
NECAP2	ITSN2	Q9NZM3	445
NECAP2	ADPRH	P54922	435
NECAP2	SNX9	Q9Y5X1	431
NECAP2	PEX39	Q5I0X4	419
NECAP2	FCHO2	Q0JRZ9	419
NECAP2	DSTYK	Q6XUX3	417
NECAP2	PITHD1	Q9GZP4	413
NECAP2	SCOC	Q9UIL1	412
NECAP2	ITSN1	Q15811	396
NECAP2	MAP7D3	Q8IWC1	393
NECAP2	EPS15L1	Q9UBC2	376
NECAP2	NRSN2	Q9GZP1	374

IntAct

38 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
AP2B1	NECAP2	psi-mi:“MI:0915”(physical association)	0.660
AP2S1	AP2A2	psi-mi:“MI:0914”(association)	0.640
NECAP2	AP2A2	psi-mi:“MI:0914”(association)	0.530
TRAF2	NECAP2	psi-mi:“MI:0915”(physical association)	0.370
PLSCR1	NECAP2	psi-mi:“MI:0915”(physical association)	0.370
NECAP2	NMI	psi-mi:“MI:0915”(physical association)	0.370
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350
SPATA1	ANKHD1	psi-mi:“MI:0914”(association)	0.350
NECAP2	ANKRD28	psi-mi:“MI:0914”(association)	0.350
RUNDC3A	GMNN	psi-mi:“MI:0914”(association)	0.350
AP2S1	AP2A2	psi-mi:“MI:0914”(association)	0.350
EPS15	KRT33A	psi-mi:“MI:0914”(association)	0.350
GOT1	A2ML1	psi-mi:“MI:0914”(association)	0.350
EVA1B	C2CD2L	psi-mi:“MI:0914”(association)	0.350
GHRL	GNPAT	psi-mi:“MI:0914”(association)	0.350
AP2B1	SYNJ1	psi-mi:“MI:0914”(association)	0.350
NECAP2	INPPL1	psi-mi:“MI:0914”(association)	0.350
AP2M1	PER1	psi-mi:“MI:0914”(association)	0.350
AP2S1	FCHO1	psi-mi:“MI:0914”(association)	0.350
FN1	ESYT2	psi-mi:“MI:0914”(association)	0.350
AP2M1	CTNND1	psi-mi:“MI:0914”(association)	0.350
CEP128	CCDC66	psi-mi:“MI:2364”(proximity)	0.270
SCLT1	VWA8	psi-mi:“MI:2364”(proximity)	0.270
CEP170	ERVK3-1	psi-mi:“MI:2364”(proximity)	0.270
FGFR1	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (109): AP2M1 (Affinity Capture-MS), AP2S1 (Affinity Capture-MS), CARM1 (Affinity Capture-MS), AP2A2 (Affinity Capture-MS), AP2A1 (Affinity Capture-MS), AP2B1 (Affinity Capture-MS), AP1B1 (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), FBXO11 (Affinity Capture-MS), AP1G1 (Affinity Capture-MS), NECAP1 (Affinity Capture-MS), TES (Affinity Capture-MS), AP1M1 (Affinity Capture-MS), ITSN1 (Affinity Capture-MS), ANKRD28 (Affinity Capture-MS)

ESM2 similar proteins: A5DUN2, C5DT65, C5E268, C5M6H7, O14056, O42921, O60200, O94264, O94581, P0CM70, P0CM71, P0CM86, P0CM87, P0CT19, P21976, P35728, P42949, P69682, Q02772, Q0UWF1, Q10113, Q17Q91, Q1K8U2, Q28GG4, Q2TAP8, Q3E731, Q3T093, Q462Q7, Q4IAJ1, Q4P821, Q4PEW9, Q54IA0, Q5AL10, Q5E9Q4, Q5R630, Q61JS7, Q6C4R1, Q6CS47, Q6FVQ3, Q6P756

Diamond homologs: P69682, Q3T093, Q5E9Q4, Q5R630, Q681Q7, Q6P756, Q8NC96, Q9CR95, Q9D1J1, Q9NVZ3, Q9VXB0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 49 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cargo recognition for clathrin-mediated endocytosis	7	21.6×	2e-06
Clathrin-mediated endocytosis	8	20.1×	5e-07
Membrane Trafficking	7	7.6×	3e-04
Vesicle-mediated transport	7	7.2×	4e-04

GO biological processes:

GO term	Partners	Fold	FDR
clathrin-dependent endocytosis	5	66.0×	3e-06
synaptic vesicle endocytosis	5	49.1×	9e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1653 predictions. Top by Δscore:

Variant	Effect	Δscore
1:16443626:CCTTA:C	acceptor_loss	1.0000
1:16443627:CTTA:C	acceptor_loss	1.0000
1:16443628:TTA:T	acceptor_loss	1.0000
1:16443629:TAGG:T	acceptor_loss	1.0000
1:16443630:A:AC	acceptor_loss	1.0000
1:16443631:G:GT	acceptor_loss	1.0000
1:16447970:AAATG:A	donor_loss	1.0000
1:16447972:ATGGT:A	donor_loss	1.0000
1:16447973:TGGT:T	donor_loss	1.0000
1:16447974:GGTA:G	donor_loss	1.0000
1:16447975:GTAG:G	donor_loss	1.0000
1:16447976:T:A	donor_loss	1.0000
1:16448142:G:GG	donor_gain	1.0000
1:16449088:CCCA:C	acceptor_loss	1.0000
1:16449090:CA:C	acceptor_loss	1.0000
1:16449091:A:AG	acceptor_gain	1.0000
1:16449091:AG:A	acceptor_gain	1.0000
1:16449091:AGGT:A	acceptor_gain	1.0000
1:16449091:AGGTG:A	acceptor_gain	1.0000
1:16449092:G:A	acceptor_loss	1.0000
1:16449092:G:GC	acceptor_gain	1.0000
1:16449092:GG:G	acceptor_gain	1.0000
1:16449092:GGT:G	acceptor_gain	1.0000
1:16449092:GGTG:G	acceptor_gain	1.0000
1:16449092:GGTGG:G	acceptor_gain	1.0000
1:16449197:TCGCA:T	donor_gain	1.0000
1:16449198:CGCA:C	donor_gain	1.0000
1:16449199:GCA:G	donor_gain	1.0000
1:16449199:GCAG:G	donor_gain	1.0000
1:16449200:CA:C	donor_gain	1.0000

AlphaMissense

1697 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:16443642:T:A	W35R	1.000
1:16443642:T:C	W35R	1.000
1:16443643:G:C	W35S	1.000
1:16443644:G:C	W35C	1.000
1:16443644:G:T	W35C	1.000
1:16443670:G:A	G44D	1.000
1:16443715:T:C	L59P	1.000
1:16447882:C:A	A69D	1.000
1:16447932:G:C	D86H	1.000
1:16447936:C:T	S87F	1.000
1:16447942:G:C	R89T	1.000
1:16447942:G:T	R89M	1.000
1:16448077:G:A	G106R	1.000
1:16448077:G:C	G106R	1.000
1:16448078:G:A	G106E	1.000
1:16448084:G:A	G108D	1.000
1:16448107:T:C	F116L	1.000
1:16448109:T:A	F116L	1.000
1:16448109:T:G	F116L	1.000
1:16449185:T:A	I158N	1.000
1:16449185:T:C	I158T	1.000
1:16440814:T:A	V18D	0.999
1:16440816:T:G	Y19D	0.999
1:16443634:C:A	A32D	0.999
1:16443663:T:A	W42R	0.999
1:16443663:T:C	W42R	0.999
1:16443665:G:C	W42C	0.999
1:16443665:G:T	W42C	0.999
1:16443669:G:C	G44R	0.999
1:16443673:G:C	R45P	0.999

dbSNP variants (sampled 300 via entrez): RS1000033591 (1:16450199 C>G,T), RS1000147663 (1:16457761 G>A), RS1000164239 (1:16457514 G>C), RS1000181434 (1:16440369 A>G), RS1000405626 (1:16444097 G>A), RS1000750329 (1:16447519 A>G,T), RS1001115816 (1:16441718 T>C), RS1001218148 (1:16440932 G>A,C), RS1001239771 (1:16439408 C>A,T), RS1001271086 (1:16439022 G>C), RS1001295595 (1:16446544 A>G), RS1001358406 (1:16453388 C>T), RS1001392065 (1:16446369 C>T), RS1001458460 (1:16444622 CT>C), RS1001460208 (1:16452371 C>A,T)

Disease associations

OMIM: gene MIM:611624 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	decreases expression	1
beta-lapachone	decreases expression	1
arsenite	increases reaction, affects binding	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol B	increases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	increases expression	1
Leflunomide	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	affects phosphorylation	1
Catechin	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Formaldehyde	increases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Phenobarbital	decreases expression	1
Phthalic Acids	increases methylation	1
Smoke	decreases expression	1
Thiram	increases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer